GNOM
Global X Genomics & Biotechnology ETF
📎 Investment Objective
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
Overview
ETF tracking Global X Genomics & Biotechnology ETF
Performance
Price Chart
Investment Summary
📎 Investment Objective
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
🎯 Investment Strategy
The fund invests in companies that are involved in the field of genomic science, such as companies engaged in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology. The fund uses a passively managed, index-based approach to track the performance of the underlying index.
✨ Key Features
- Provides exposure to companies at the forefront of genomic science and biotechnology innovation
- Passively managed index-tracking fund with low expense ratio
- Diversified portfolio across the genomics and biotechnology sectors
- Suitable for investors seeking targeted exposure to the genomics and biotechnology theme
⚠️ Primary Risks
- Sector concentration risk: The fund's performance is closely tied to the genomics and biotechnology sectors, which may be subject to greater volatility and risk than the broader market
- Equity market risk: The value of the fund's holdings may decline due to general market and economic conditions
- Regulatory risk: Changes in government regulations or policies affecting the genomics and biotechnology industries could adversely impact the fund's performance
- Liquidity risk: The fund may have difficulty trading certain securities at an optimal price due to low trading volume
👤 Best For
The Global X Genomics & Biotechnology ETF may be suitable for long-term investors with a higher risk tolerance who are seeking exposure to the growth potential of the genomics and biotechnology sectors as part of a diversified portfolio. Investors should be aware of the fund's sector concentration and the associated risks.